STOCK TITAN

Bio-Path Holdings Inc - $BPTH STOCK NEWS

Welcome to our dedicated page for Bio-Path Holdings news (Ticker: $BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Path Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Path Holdings's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
126.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.69%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences
Bio-Path Holdings Inc

Nasdaq:BPTH

BPTH Rankings

BPTH Stock Data

4.26M
628.47k
0.23%
3.73%
9.93%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BELLAIRE

About BPTH

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen